PTCT Earnings Prediction
The chart below shows how PTCT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PTCT sees a -1.34% change in stock price 10 days leading up to the earnings, and a +0.64% change 10 days following the report. On the earnings day itself, the stock moves by +0.37%. This data can give you a slight idea of what to expect for the next quarter's release.
PTCT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
196.79M
0.11%
5.40%
Gross Margin
92.94%
42.24%
3.09%
Operating Margin
-26.41%
-44.81%
47.79%
Net Margin
-54.20%
-19.87%
2.03%
EPS
-1.39
-21.02%
7.75%
No Data Available
PTCT Earnings Analysis
PTC Therapeutics, Inc. Corporation (PTCT.O) Earnings Conference Call
Positive
Third Quarter Revenue Breakdown: Total revenue for the third quarter was $197 million, including DMD franchise revenue of $124 million.
Product Revenue Comparison: Translarna net product revenue in the quarter was $72 million, while Emflaza net product revenue of $52 million.
Global Net Revenue Achievement: Third quarter global net revenue of approximately $460 million was achieved by Roche resulting in royalty revenue of $61 million for PTC.
R&D Expense Comparison: Non-GAAP R&D expense was $152 million for the third quarter of 2024, compared to $150 million for the third quarter of 2023, excluding $9 million in non-cash stock-based compensation expense.
Strategic Financial Position: Our strong financial position provides PTC with the necessary resources to execute on our strategy and achieve our milestones over the next several years, including the anticipated launch of sepipaterin and other products.
Negative
Third Quarter Revenue Decline: Total revenue for the third quarter was $197 million, including DMD franchise revenue of $124 million, indicating a decline in overall revenue performance.
Quarterly Revenue Comparison: Translarna net product revenue in the quarter was $72 million, while Emflaza net product revenue of $52 million shows a decrease in revenue generation.
R&D Expense Increase: Non-GAAP R&D expense was $152 million for the third quarter of 2024, compared to $150 million for the third quarter of 2023, indicating rising costs without corresponding revenue growth.
SG&A Expense Comparison: Non-GAAP SG&A expense was $63 million for the third quarter of 2024, compared to $68 million for the third quarter of 2023, reflecting increased operational costs despite revenue challenges.
Liquidity Position Analysis: Cash, cash equivalents and marketable securities totaled $1.0 billion as of September 30, 2024, compared to $877 billion as of December 31, 2023, suggesting a potential liquidity issue despite a strong cash position.
PTCT FAQs
How does PTCT typically perform around its earnings report dates?
Is PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PTCT Earning Call Sentiment
PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PTCT.O
1.19%Positive
The earnings call highlights strong financial performance with increased total revenue and a solid cash position. The potential revenue from Sepiapterin and the upcoming Vatiquinone launch provide positive future prospects. The Q&A session revealed excitement from providers about new therapies and expectations of strong future revenue, despite some concerns about European sales and unclear FDA meeting outcomes. Overall, the positive financials and optimistic product outlook suggest a likely positive stock price movement.
